Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Basel, 16. Oktober 2014 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Astellas Pharma Inc. bei den entsprechenden Zulassungsbehörden und Ethikkommissionen eine Änderung...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Follow today's event live08:30 CET Sales...
-
Basel, Switzerland, October 16, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its partner Astellas Pharma Inc. has filed an amendment to the phase 3 ACTIVE study protocol with...
-
Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019[1] Largest...
-
Zurich / Switzerland, 15 October 2014ARYZTA AG is making the following attached regulatory submission in accordance with the requirements of its secondary listing on the Irish Stock Exchange (ISE)....
-
Zurich / Switzerland, 15 October 2014ARYZTA AG's 68.1% subsidiary, Origin Enterprises Plc, which is listed on the AIM in London (OGN) and the ESM in Dublin (OIZ), has made a regulatory announcement...
-
New analyses of Phase III data show consistent efficacy in clearing psoriasis skin with AIN457 (secukinumab) regardless of how bad patients' disease is at start of treatment[1] Significant...
-
Annual economic impact equals more than 350,000 healthy life years lost and over €20 billion EUR as a result of blindness for 14 countries studied Screening for diabetic retinopathy, cataracts...
-
Basel, 8. Oktober 2014 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass auf der Fachkonferenz für Infektionskrankheiten IDWeek 2014 weitere Analysen zu Patientensubgruppen sowie...
-
Basel, Switzerland, October 08, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that further subgroup and health economic analyses of data from the phase 3 studies SECURE and VITAL...